GLMD Galmed Pharmaceuticals Ltd. - O

+0.01  (0%)
Previous Close 6.01
Open 6.27
Price To book 8.81
Market Cap 73.25M
Shares 12,168,000
Volume 35,893
Short Ratio 2.50
Av. Daily Volume 36,311

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b enrollment complettion announced January 9, 2017. Data due 2Q 2018.
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2 initiated dosing February 2016
Aramchol - ARRIVE
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)

Latest News

  1. Galmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors
  2. Galmed Pharmaceuticals reports 1Q loss
  3. Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results
  4. Galmed Pharmaceuticals First Quarter 2017 Conference Call and Webcast Scheduled for Monday, May 15th, 2017
  5. Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol™ has a Potential Direct Effect on Liver Fibrosis
  6. Galmed Pharmaceuticals Fourth Quarter 2016 Conference Call and Webcast Scheduled for Thursday, March 23rd, 2017
  7. Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
  8. Galmed Pharmaceuticals Third Quarter 2016 Conference Call and Webcast Scheduled for Monday, November 7th, 2016
  9. Galmed Pharmaceuticals Announces that it has Raised Approximately $5.0 Million to Date Under its ATM Program
  10. 5 Biotech Stocks to Watch as Interest in NASH Increases
  11. These Biotech Names Are on My Radar
  12. Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer
  13. Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
  14. Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer
  15. Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol™ in Korea